{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:31:22Z","timestamp":1780385482842,"version":"3.54.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR074457"],"award-info":[{"award-number":["R01AR074457"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50HD087351"],"award-info":[{"award-number":["P50HD087351"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Valosin-containing protein (VCP) associated multisystem proteinopathy (MSP) is a rare inherited disorder that may result in multisystem involvement of varying phenotypes including inclusion body myopathy, Paget\u2019s disease of bone (PDB), frontotemporal dementia (FTD), parkinsonism, and amyotrophic lateral sclerosis (ALS), among others. An international multidisciplinary consortium of 40+ experts in neuromuscular disease, dementia, movement disorders, psychology, cardiology, pulmonology, physical therapy, occupational therapy, speech and language pathology, nutrition, genetics, integrative medicine, and endocrinology were convened by the patient advocacy organization, Cure VCP Disease, in December 2020 to develop a standard of care for this heterogeneous and under-diagnosed disease. To achieve this goal, working groups collaborated to generate expert consensus recommendations in 10 key areas: genetic diagnosis, myopathy, FTD, PDB, ALS, Charcot Marie Tooth disease (CMT), parkinsonism, cardiomyopathy, pulmonology, supportive therapies, nutrition and supplements, and mental health. In April 2021, facilitated discussion of each working group\u2019s conclusions with consensus building techniques enabled final agreement on the proposed standard of care for VCP patients. Timely referral to a specialty neuromuscular center is recommended to aid in efficient diagnosis of VCP MSP via single-gene testing in the case of a known familial VCP variant, or multi-gene panel sequencing in undifferentiated cases. Additionally, regular and ongoing multidisciplinary team follow up is essential for proactive screening and management of secondary complications. The goal of our consortium is to raise awareness of VCP MSP, expedite the time to accurate diagnosis, define gaps and inequities in patient care, initiate appropriate pharmacotherapies and supportive therapies for optimal management, and elevate the recommended best practices guidelines for multidisciplinary care internationally.\n<\/jats:p>","DOI":"10.1186\/s13023-022-02172-5","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T11:03:39Z","timestamp":1643454219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4626-4007","authenticated-orcid":false,"given":"Manisha","family":"Korb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Peck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay N.","family":"Alfano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth I.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith K.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nupur","family":"Ghoshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Healzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Henchcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaida","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep P. A.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H.","family":"Ralston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Seeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Swenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahseen","family":"Mozaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Weihl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Kimonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the VCP Standards of Care Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Fanganiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan Patrick","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Diaz-Manera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresinha","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Freimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benison","family":"Keung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Kushlaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Milone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrilee","family":"Needham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Palmio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Stojkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo-Nur","family":"Villar-Quiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo H.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Wicklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ahmad Sajjadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Obenaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Geschwind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"Al-Chalabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Kompoliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephani C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Boissoneault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsaida","family":"Cruz-Coble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendrea L.","family":"Garand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna J.","family":"Rinholen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Tabor-Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Peck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,29]]},"reference":[{"key":"2172_CR1","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/mus.27097","volume":"63","author":"MK Korb","year":"2021","unstructured":"Korb MK, Kimonis VE, Mozaffar T. Multisystem proteinopathy: where myopathy and motor neuron disease converge. Muscle Nerve. 2021;63:442\u201354.","journal-title":"Muscle Nerve"},{"key":"2172_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/ana.26136","volume":"90","author":"TB Leoni","year":"2021","unstructured":"Leoni TB, Gonzalez-Salazar C, Rezende TJR, et al. A novel multisystem proteinopathy caused by a Missense ANXA11 variant. Ann Neurol. 2021;90:239\u201352.","journal-title":"Ann Neurol"},{"key":"2172_CR3","first-page":"1193","volume":"121","author":"N Hill","year":"1979","unstructured":"Hill N, Frappier-Davignon L, Morrison B. The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J. 1979;121:1193\u2013254.","journal-title":"Can Med Assoc J"},{"key":"2172_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/cge.13095","volume":"93","author":"E Al-Obeidi","year":"2018","unstructured":"Al-Obeidi E, Al-Tahan S, Surampalli A, et al. Genotype\u2013phenotype study in patients with valosin-containing protein mutations associated with multisystem proteinopathy. Clin Genet. 2018;93:119\u201325.","journal-title":"Clin Genet"},{"key":"2172_CR5","first-page":"3877","volume":"127","author":"H Meyer","year":"2014","unstructured":"Meyer H, Weihl CC. The VCP\/p97 system at a glance: connecting cellular function to disease pathogenesis. J Cell Sci. 2014;127:3877\u201383.","journal-title":"J Cell Sci"},{"key":"2172_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.molcel.2017.10.028","volume":"69","author":"J van den Boom","year":"2018","unstructured":"van den Boom J, Meyer H. VCP\/p97-mediated unfolding as a principle in protein homeostasis and signaling. Mol Cell. 2018;69:182\u201394.","journal-title":"Mol Cell"},{"key":"2172_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/ng1332","volume":"36","author":"GD Watts","year":"2004","unstructured":"Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36:377\u201381.","journal-title":"Nat Genet"},{"key":"2172_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.nmd.2018.04.007","volume":"28","author":"S Al-Tahan","year":"2018","unstructured":"Al-Tahan S, Al-Obeidi E, Yoshioka H, et al. Novel valosin-containing protein mutations associated with multisystem proteinopathy. Neuromuscul Disord. 2018;28:491\u2013501.","journal-title":"Neuromuscul Disord"},{"key":"2172_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature11922","volume":"495","author":"HJ Kim","year":"2013","unstructured":"Kim HJ, Kim NC, Wang YD, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495:467\u201373.","journal-title":"Nature"},{"key":"2172_CR10","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1212\/WNL.0000000000001864","volume":"85","author":"RC Bucelli","year":"2015","unstructured":"Bucelli RC, Arhzaouy K, Pestronk A, et al. SQSTM1 splice site mutation in distal myopathy with rimmed vacuoles. Neurology. 2015;85:665\u201374.","journal-title":"Neurology"},{"key":"2172_CR11","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1212\/WNL.0000000000001862","volume":"85","author":"JP Taylor","year":"2015","unstructured":"Taylor JP. Multisystem proteinopathy: intersecting genetics in muscle, bone, and brain degeneration. Neurology. 2015;85:658\u201360.","journal-title":"Neurology"},{"issue":"36","key":"2172_CR12","first-page":"e2001","volume":"2015","author":"KP Lin","year":"2005","unstructured":"Lin KP, Tsai PC, Liao YC, et al. Mutational analysis of MATR3 in Taiwanese patients with amyotrophic lateral sclerosis. Neurobiol Aging. 2005;2015(36):e2001\u20134.","journal-title":"Neurobiol Aging"},{"key":"2172_CR13","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.neuron.2017.07.025","volume":"95","author":"IR Mackenzie","year":"2017","unstructured":"Mackenzie IR, Nicholson AM, Sarkar M, et al. TIA1 mutations in amyotrophic lateral sclerosis and frontotemporal dementia promote phase separation and alter stress granule dynamics. Neuron. 2017;95:808\u2013816.e809.","journal-title":"Neuron"},{"key":"2172_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nature08971","volume":"465","author":"H Maruyama","year":"2010","unstructured":"Maruyama H, Morino H, Ito H, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223\u20136.","journal-title":"Nature"},{"key":"2172_CR15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/ng.562","volume":"42","author":"OM Albagha","year":"2010","unstructured":"Albagha OM, Visconti MR, Alonso N, et al. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget\u2019s disease of bone. Nat Genet. 2010;42:520\u20134.","journal-title":"Nat Genet"},{"key":"2172_CR16","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/jbmr.3964","volume":"35","author":"F Scotto di Carlo","year":"2020","unstructured":"Scotto di Carlo F, Pazzaglia L, Esposito T, Gianfrancesco F. The loss of profilin 1 causes early onset Paget\u2019s disease of bone. J Bone Miner Res. 2020;35:1387\u201398.","journal-title":"J Bone Miner Res"},{"key":"2172_CR17","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1210\/clinem\/dgaa252","volume":"105","author":"D Merlotti","year":"2020","unstructured":"Merlotti D, Materozzi M, Bianciardi S, et al. Mutation of PFN1 gene in an early onset, polyostotic Paget-like disease. J Clin Endocrinol Metab. 2020;105:2553\u201365.","journal-title":"J Clin Endocrinol Metab"},{"key":"2172_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nature11280","volume":"488","author":"CH Wu","year":"2012","unstructured":"Wu CH, Fallini C, Ticozzi N, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012;488:499\u2013503.","journal-title":"Nature"},{"key":"2172_CR19","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.nmd.2009.01.009","volume":"19","author":"CC Weihl","year":"2009","unstructured":"Weihl CC, Pestronk A, Kimonis VE. Valosin-containing protein disease: inclusion body myopathy with Paget\u2019s disease of the bone and fronto-temporal dementia. Neuromuscul Disord. 2009;19:308\u201315.","journal-title":"Neuromuscul Disord"},{"key":"2172_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"2172_CR21","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s10897-013-9678-z","volume":"23","author":"TM Scuffham","year":"2014","unstructured":"Scuffham TM, MacMillan JC. Huntington disease: who seeks presymptomatic genetic testing, why and what are the outcomes? J Genet Couns. 2014;23:754\u201361.","journal-title":"J Genet Couns"},{"key":"2172_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10897-014-9755-y","volume":"24","author":"S Crozier","year":"2015","unstructured":"Crozier S, Robertson N, Dale M. The psychological impact of predictive genetic testing for Huntington\u2019s disease: a systematic review of the literature. J Genet Couns. 2015;24:29\u201339.","journal-title":"J Genet Couns"},{"key":"2172_CR23","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/jgc4.1245","volume":"29","author":"KH Tilleras","year":"2020","unstructured":"Tilleras KH, Kjoelaas SH, Dramstad E, Feragen KB, von der Lippe C. Psychological reactions to predictive genetic testing for Huntington\u2019s disease: a qualitative study. J Genet Couns. 2020;29:1093\u2013105.","journal-title":"J Genet Couns"},{"key":"2172_CR24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/cge.12000","volume":"83","author":"SG Mehta","year":"2013","unstructured":"Mehta SG, Khare M, Ramani R, et al. Genotype\u2013phenotype studies of VCP-associated inclusion body myopathy with Paget disease of bone and\/or frontotemporal dementia. Clin Genet. 2013;83:422\u201331.","journal-title":"Clin Genet"},{"key":"2172_CR25","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3389\/fneur.2018.00456","volume":"9","author":"E Bugiardini","year":"2018","unstructured":"Bugiardini E, Morrow JM, Shah S, et al. The diagnostic value of MRI pattern recognition in distal myopathies. Front Neurol. 2018;9:456.","journal-title":"Front Neurol"},{"key":"2172_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.nmd.2016.05.017","volume":"26","author":"T Evangelista","year":"2016","unstructured":"Evangelista T, Weihl CC, Kimonis V, Lochmuller H, Consortium VCPrd. 215th ENMC International Workshop VCP-related multi-system proteinopathy (IBMPFD) 13\u201315 November 2015, Heemskerk, The Netherlands. Neuromuscul Disord. 2016;26:535\u201347.","journal-title":"Neuromuscul Disord"},{"key":"2172_CR27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/mus.24980","volume":"54","author":"M Kazamel","year":"2016","unstructured":"Kazamel M, Sorenson EJ, McEvoy KM, et al. Clinical spectrum of valosin containing protein (VCP)-opathy. Muscle Nerve. 2016;54:94\u20139.","journal-title":"Muscle Nerve"},{"key":"2172_CR28","first-page":"95","volume":"34","author":"J Diaz-Manera","year":"2015","unstructured":"Diaz-Manera J, Llauger J, Gallardo E, Illa I. Muscle MRI in muscular dystrophies. Acta Myol. 2015;34:95\u2013108.","journal-title":"Acta Myol"},{"key":"2172_CR29","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/jnnp.2007.131334","volume":"79","author":"CC Weihl","year":"2008","unstructured":"Weihl CC, Temiz P, Miller SE, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2008;79:1186\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2172_CR30","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1136\/jnnp-2015-310362","volume":"87","author":"S Figueroa-Bonaparte","year":"2016","unstructured":"Figueroa-Bonaparte S, Hudson J, Barresi R, et al. Mutational spectrum and phenotypic variability of VCP-related neurological disease in the UK. J Neurol Neurosurg Psychiatry. 2016;87:680\u20131.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2172_CR31","doi-asserted-by":"publisher","first-page":"e0176919","DOI":"10.1371\/journal.pone.0176919","volume":"12","author":"KJ Llewellyn","year":"2017","unstructured":"Llewellyn KJ, Nalbandian A, Weiss LN, et al. Myogenic differentiation of VCP disease-induced pluripotent stem cells: a novel platform for drug discovery. PLoS ONE. 2017;12:e0176919.","journal-title":"PLoS ONE"},{"key":"2172_CR32","doi-asserted-by":"publisher","first-page":"e17834","DOI":"10.7554\/eLife.17834","volume":"6","author":"T Zhang","year":"2017","unstructured":"Zhang T, Mishra P, Hay BA, Chan D, Guo M. Valosin-containing protein (VCP\/p97) inhibitors relieve mitofusin-dependent mitochondrial defects due to VCP disease mutants. Elife. 2017;6:e17834.","journal-title":"Elife"},{"key":"2172_CR33","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.molcel.2019.03.027","volume":"74","author":"B Wang","year":"2019","unstructured":"Wang B, Maxwell BA, Joo JH, et al. ULK1 and ULK2 regulate stress granule disassembly through phosphorylation and activation of VCP\/p97. Mol Cell. 2019;74:742-757.e748.","journal-title":"Mol Cell"},{"key":"2172_CR34","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/archneurol.2010.376","volume":"68","author":"EJ Kim","year":"2011","unstructured":"Kim EJ, Park YE, Kim DS, et al. Inclusion body myopathy with Paget disease of bone and frontotemporal dementia linked to VCP p.Arg155Cys in a Korean family. Arch Neurol. 2011;68:787\u201396.","journal-title":"Arch Neurol"},{"key":"2172_CR35","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1093\/brain\/awaa018","volume":"143","author":"S Ducharme","year":"2020","unstructured":"Ducharme S, Dols A, Laforce R, et al. Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain. 2020;143:1632\u201350.","journal-title":"Brain"},{"key":"2172_CR36","first-page":"203","volume":"36","author":"GK Papadimas","year":"2017","unstructured":"Papadimas GK, Paraskevas GP, Zambelis T, et al. The multifaceted clinical presentation of VCP-proteinopathy in a Greek family. Acta Myol. 2017;36:203\u20136.","journal-title":"Acta Myol"},{"key":"2172_CR37","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/brain\/awl238","volume":"130","author":"CU Hubbers","year":"2007","unstructured":"Hubbers CU, Clemen CS, Kesper K, et al. Pathological consequences of VCP mutations on human striated muscle. Brain. 2007;130:381\u201393.","journal-title":"Brain"},{"key":"2172_CR38","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456\u201377.","journal-title":"Brain"},{"key":"2172_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/alz.12001","volume":"16","author":"KB Casaletto","year":"2020","unstructured":"Casaletto KB, Staffaroni AM, Wolf A, et al. Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration. Alzheimers Dement. 2020;16:91\u2013105.","journal-title":"Alzheimers Dement"},{"issue":"Suppl","key":"2172_CR40","first-page":"133","volume":"22","author":"V Kiousi","year":"2019","unstructured":"Kiousi V, Arnaoutoglou M, Printza A. Speech and language intervention for language impairment in patients in the FTD-ALS spectrum. Hell J Nucl Med. 2019;22(Suppl):133\u201346.","journal-title":"Hell J Nucl Med"},{"key":"2172_CR41","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11940-014-0319-0","volume":"16","author":"RM Tsai","year":"2014","unstructured":"Tsai RM, Boxer AL. Treatment of frontotemporal dementia. Curr Treat Options Neurol. 2014;16:319.","journal-title":"Curr Treat Options Neurol"},{"key":"2172_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13195-020-00753-9","volume":"13","author":"M Leroy","year":"2021","unstructured":"Leroy M, Bertoux M, Skrobala E, et al. Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network. Alzheimers Res Ther. 2021;13:19.","journal-title":"Alzheimers Res Ther"},{"key":"2172_CR43","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40266-019-00685-6","volume":"36","author":"P Noufi","year":"2019","unstructured":"Noufi P, Khoury R, Jeyakumar S, Grossberg GT. Use of cholinesterase inhibitors in non-Alzheimer\u2019s dementias. Drugs Aging. 2019;36:719\u201331.","journal-title":"Drugs Aging"},{"key":"2172_CR44","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1474-4422(12)70320-4","volume":"12","author":"AL Boxer","year":"2013","unstructured":"Boxer AL, Knopman DS, Kaufer DI, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:149\u201356.","journal-title":"Lancet Neurol"},{"key":"2172_CR45","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.2002.17.3.465","volume":"17","author":"TP van Staa","year":"2002","unstructured":"van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C. Incidence and natural history of Paget\u2019s disease of bone in England and Wales. J Bone Miner Res. 2002;17:465\u201371.","journal-title":"J Bone Miner Res"},{"key":"2172_CR46","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/qjmed\/hcu075","volume":"107","author":"A Tan","year":"2014","unstructured":"Tan A, Ralston SH. Paget\u2019s disease of bone. QJM. 2014;107:865\u20139.","journal-title":"QJM"},{"key":"2172_CR47","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/jbmr.3873","volume":"34","author":"SH Ralston","year":"2019","unstructured":"Ralston SH, Corral-Gudino L, Cooper C, et al. Diagnosis and management of Paget\u2019s disease of bone in adults: a clinical guideline. J Bone Miner Res. 2019;34:579\u2013604.","journal-title":"J Bone Miner Res"},{"key":"2172_CR48","doi-asserted-by":"publisher","first-page":"115465","DOI":"10.1016\/j.bone.2020.115465","volume":"138","author":"SH Ralston","year":"2020","unstructured":"Ralston SH. Bisphosphonates in the management of Paget\u2019s disease. Bone. 2020;138:115465.","journal-title":"Bone"},{"key":"2172_CR49","doi-asserted-by":"publisher","first-page":"e466","DOI":"10.1210\/clinem\/dgz138","volume":"105","author":"D Merlotti","year":"2020","unstructured":"Merlotti D, Rendina D, Muscariello R, et al. Preventive role of vitamin D supplementation for acute phase reaction after bisphosphonate infusion in Paget\u2019s disease. J Clin Endocrinol Metab. 2020;105:e466\u201376.","journal-title":"J Clin Endocrinol Metab"},{"key":"2172_CR50","doi-asserted-by":"publisher","first-page":"e030689","DOI":"10.1136\/bmjopen-2019-030689","volume":"9","author":"O Cronin","year":"2019","unstructured":"Cronin O, Forsyth L, Goodman K, et al. Zoledronate in the prevention of Paget\u2019s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget\u2019s disease of bone. BMJ Open. 2019;9:e030689.","journal-title":"BMJ Open"},{"key":"2172_CR51","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/jbmr.3066","volume":"32","author":"A Tan","year":"2017","unstructured":"Tan A, Goodman K, Walker A, et al. Long-term randomized trial of intensive versus symptomatic management in Paget\u2019s disease of bone: the PRISM-EZ study. J Bone Miner Res. 2017;32:1165\u201373.","journal-title":"J Bone Miner Res"},{"key":"2172_CR52","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/146608200300079536","volume":"1","author":"BR Brooks","year":"2000","unstructured":"Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293\u20139.","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"2172_CR53","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.clinph.2007.09.143","volume":"119","author":"M de Carvalho","year":"2008","unstructured":"de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119:497\u2013503.","journal-title":"Clin Neurophysiol"},{"key":"2172_CR54","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/ana.26045","volume":"89","author":"A Hannaford","year":"2021","unstructured":"Hannaford A, Pavey N, van den Bos M, et al. Diagnostic utility of gold coast criteria in amyotrophic lateral sclerosis. Ann Neurol. 2021;89:979\u201386.","journal-title":"Ann Neurol"},{"key":"2172_CR55","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/j.1468-1331.2011.03501.x","volume":"19","author":"PM Andersen","year":"2012","unstructured":"Diagnosis ETFo, Management of Amyotrophic Lateral S, Andersen PM, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)\u2014revised report of an EFNS task force. Eur J Neurol. 2012;19:360\u201375.","journal-title":"Eur J Neurol"},{"key":"2172_CR56","first-page":"239167","volume":"2015","author":"NU Jerath","year":"2015","unstructured":"Jerath NU, Crockett CD, Moore SA, et al. Rare manifestation of a c.290 C>T, p.Gly97Glu VCP mutation. Case Rep Genet. 2015;2015:239167.","journal-title":"Case Rep Genet"},{"key":"2172_CR57","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1093\/brain\/awu224","volume":"137","author":"MA Gonzalez","year":"2014","unstructured":"Gonzalez MA, Feely SM, Speziani F, et al. A novel mutation in VCP causes Charcot-Marie-Tooth Type 2 disease. Brain. 2014;137:2897\u2013902.","journal-title":"Brain"},{"key":"2172_CR58","doi-asserted-by":"publisher","first-page":"e785","DOI":"10.1212\/WNL.0000000000008763","volume":"94","author":"W De Ridder","year":"2019","unstructured":"De Ridder W, Azmi A, Clemen CS, et al. Multisystem proteinopathy due to a homozygous p.Arg159His VCP mutation: a tale of the unexpected. Neurology. 2019;94:e785\u201396.","journal-title":"Neurology"},{"key":"2172_CR59","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30:1591\u2013601.","journal-title":"Mov Disord"},{"key":"2172_CR60","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/00125817-200007000-00006","volume":"2","author":"VE Kimonis","year":"2000","unstructured":"Kimonis VE, Kovach MJ, Waggoner B, et al. Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone. Genet Med. 2000;2:232\u201341.","journal-title":"Genet Med"},{"key":"2172_CR61","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1161\/CIR.0000000000000526","volume":"136","author":"B Feingold","year":"2017","unstructured":"Feingold B, Mahle WT, Auerbach S, et al. Management of cardiac involvement associated with neuromuscular diseases: a scientific statement from the American Heart Association. Circulation. 2017;136:e200\u201331.","journal-title":"Circulation"},{"key":"2172_CR62","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.bbadis.2008.09.003","volume":"1782","author":"VE Kimonis","year":"2008","unstructured":"Kimonis VE, Fulchiero E, Vesa J, Watts G. VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder. Biochim Biophys Acta. 2008;1782:744\u20138.","journal-title":"Biochim Biophys Acta"},{"key":"2172_CR63","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.nmd.2021.06.005","volume":"31","author":"SC Wang","year":"2021","unstructured":"Wang SC, Smith CD, Lombardo DM, Kimonis V. Characteristics of VCP mutation-associated cardiomyopathy. Neuromuscul Disord. 2021;31:701\u20135.","journal-title":"Neuromuscul Disord"},{"key":"2172_CR64","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s13023-020-01551-0","volume":"15","author":"C Ikenaga","year":"2020","unstructured":"Ikenaga C, Findlay AR, Seiffert M, et al. Phenotypic diversity in an international Cure VCP Disease registry. Orphanet J Rare Dis. 2020;15:267.","journal-title":"Orphanet J Rare Dis"},{"key":"2172_CR65","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.nmd.2018.06.007","volume":"28","author":"J Plewa","year":"2018","unstructured":"Plewa J, Surampalli A, Wencel M, et al. A cross-sectional analysis of clinical evaluation in 35 individuals with mutations of the valosin-containing protein gene. Neuromuscul Disord. 2018;28:778\u201386.","journal-title":"Neuromuscul Disord"},{"key":"2172_CR66","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1164\/rccm.200307-885ST","volume":"170","author":"JD Finder","year":"2004","unstructured":"Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med. 2004;170:456\u201365.","journal-title":"Am J Respir Crit Care Med"},{"key":"2172_CR67","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1136\/thorax.57.8.724","volume":"57","author":"R Ragette","year":"2002","unstructured":"Ragette R, Mellies U, Schwake C, Voit T, Teschler H. Patterns and predictors of sleep disordered breathing in primary myopathies. Thorax. 2002;57:724\u20138.","journal-title":"Thorax"},{"key":"2172_CR68","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s12031-011-9627-y","volume":"45","author":"A Nalbandian","year":"2011","unstructured":"Nalbandian A, Donkervoort S, Dec E, et al. The multiple faces of valosin-containing protein-associated diseases: inclusion body myopathy with Paget\u2019s disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis. J Mol Neurosci. 2011;45:522\u201331.","journal-title":"J Mol Neurosci"},{"key":"2172_CR69","doi-asserted-by":"publisher","first-page":"e76187","DOI":"10.1371\/journal.pone.0076187","volume":"8","author":"A Nalbandian","year":"2013","unstructured":"Nalbandian A, Nguyen C, Katheria V, et al. Exercise training reverses skeletal muscle atrophy in an experimental model of VCP disease. PLoS ONE. 2013;8:e76187.","journal-title":"PLoS ONE"},{"key":"2172_CR70","doi-asserted-by":"publisher","first-page":"46","DOI":"10.6000\/1927-3037.2014.03.02.2","volume":"3","author":"V Kimonis","year":"2014","unstructured":"Kimonis V, Hamorsky K, Surampalli A, Wencel M, Khare M. The influence of diet and exercise on the physical health of affected individuals with VCP diseae. Int J Biotechnol Wellness Ind. 2014;3:46\u201352.","journal-title":"Int J Biotechnol Wellness Ind"},{"key":"2172_CR71","doi-asserted-by":"publisher","first-page":"S225","DOI":"10.1044\/1092-4388(2008\/018)","volume":"51","author":"JA Kleim","year":"2008","unstructured":"Kleim JA, Jones TA. Principles of experience-dependent neural plasticity: implications for rehabilitation after brain damage. J Speech Lang Hear Res. 2008;51:S225\u201339.","journal-title":"J Speech Lang Hear Res"},{"key":"2172_CR72","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1037\/hea0000840","volume":"39","author":"KR Bogart","year":"2020","unstructured":"Bogart KR, Dermody SS. Relationship of rare disorder latent clusters to anxiety and depression symptoms. Health Psychol. 2020;39:307\u201315.","journal-title":"Health Psychol"},{"key":"2172_CR73","unstructured":"A standard framework for levels of integrated healthcare and update throughout the document. Available at https:\/\/www.integration.samhsa.gov\/integrated-care-models\/A_Standard_Framework_for_Levels_of_Integrated_Healthcare.pdf. Accessed 13 May 2020."},{"key":"2172_CR74","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.urology.2019.09.039","volume":"135","author":"JD Roth","year":"2020","unstructured":"Roth JD, Pariser JJ, Stout TE, Misseri R, Elliott SP. Presentation and management patterns of lower urinary tract symptoms in adults due to rare inherited neuromuscular diseases. Urology. 2020;135:165\u201370.","journal-title":"Urology"},{"key":"2172_CR75","doi-asserted-by":"publisher","first-page":"e0233527","DOI":"10.1371\/journal.pone.0233527","volume":"15","author":"CI Morse","year":"2020","unstructured":"Morse CI, Higham K, Bostock EL, Jacques MF. Urinary incontinence in men with Duchenne and Becker muscular dystrophy. PLoS ONE. 2020;15:e0233527.","journal-title":"PLoS ONE"},{"key":"2172_CR76","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.nmd.2019.05.009","volume":"29","author":"RKH Petty","year":"2019","unstructured":"Petty RKH, Eugenicos MP, Hamilton MJ, et al. The prevalence of faecal incontinence in myotonic dystrophy type 1. Neuromuscul Disord. 2019;29:562\u20136.","journal-title":"Neuromuscul Disord"},{"key":"2172_CR77","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/hmg\/ddt523","volume":"23","author":"KJ Llewellyn","year":"2014","unstructured":"Llewellyn KJ, Nalbandian A, Jung KM, et al. Lipid-enriched diet rescues lethality and slows down progression in a murine model of VCP-associated disease. Hum Mol Genet. 2014;23:1333\u201344.","journal-title":"Hum Mol Genet"},{"key":"2172_CR78","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/NT.0000000000000228","volume":"52","author":"DF Romagnolo","year":"2017","unstructured":"Romagnolo DF, Selmin OI. Mediterranean diet and prevention of chronic diseases. Nutr Today. 2017;52:208\u201322.","journal-title":"Nutr Today"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02172-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02172-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02172-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T23:08:49Z","timestamp":1666307329000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02172-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2172"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02172-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,29]]},"assertion":[{"value":"8 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript does not report on or involve the use of any animal or human data or tissue.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This manuscript does not contain any individual persons\u2019 data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MK has served on advisory boards for Biogen, Argenx, and CSL Behring, and on the speaker's bureau for Biogen. AP does not have any competing interests to disclose. LA reports grant support from Cure VCP Disease; provides consultancy services for training and quality control through ATOM International for the following companies: Amicus Therapeutics Pty Ltd, Catabasis, Genethon, Italfarmaco, NS Pharma, Pfizer, PTC Therapeutics; reports royalties and other support through Nationwide Children\u2019s Hospital from Sarepta Therapeutics; royalties for licensed technologies; other support through Nationwide Children\u2019s Hospital from Novartis Gene Therapies; advisory board for Biogen. KB has consulted for and\/or served as a member of advisory boards for Sanofi\u2014Genzyme, Inventiva Pharma, Amicus Therapeutics, Valerion Therapeutics, and Spark Therapeutics. MJ provides consultancy services for the following companies: ATOM International (covers consultancy services provided to Amicus Therapeutics Pty Ltd, Ascendis Pharma, Biomarin, Catabasis, Faraday, FibroGen, Genethon, Italfarmaco, NS Pharma, Pfizer, PTC Therapeutics, QED Therapeutics Ltd, Reveragen, Sarepta Therapeutics, outside the submitted work. MKJ has received payment for participation on Advisory Boards for F. Hoffman La Roche AG, PTC Therapeutics and fee support for PhD studies from the Jain Foundation, outside the submitted work. NG has participated or is currently participating in clinical trials of anti-dementia drugs sponsored by the following companies: Bristol Myers Squibb, Eli Lilly\/Avid Radiopharmaceuticals, Janssen Immunotherapy, Novartis, Pfizer, Wyeth, SNIFF (The Study of Nasal Insulin to Fight Forgetfulness) study, and A4 (The Anti-Amyloid Treatment in Asymptomatic Alzheimer\u2019s Disease) trial. She receives research support from NIH, Tau Consortium, and the Association for Frontotemporal Degeneration. EH does not have any competing interests to disclose. CH has served on advisory boards for Axent Biosciences Inc, Acorda Therapeutics, Amneal Pharmaceuticals, Mitsubishi Tanabe Pharma, and US WorldMeds, and as a consultant for Zywie Bio. SK has served on advisory boards for Alexion Pharmaceuticals, Inc, UCB Pharmaceuticals, Inc, Immunovant, Inc, and Argenx. PM declares the following competing interests: American Heart Association (member of the AHA Career Development Research Grant Committee), California Institute of Regenerative Medicine (member of the Grants Working Group), CareDx Inc. (Site PI for the SHORE Registry), Catabasis Inc. (research grant), Dyne Therapeutics (consultant and member of the DMD Scientific Advisory Board), National Institute of Health (research grants and ad hoc grant reviewer for the NIH SMEP and MOSS Study Sections), Novartis Gene Therapies (member of the Data Monitoring and Safety Committee), and PhaseBio Inc. (research grant and member of the Scientific Advisory Board). SP owns a wellness company for supplements called Wellness with Sujata. GP does not have any competing interests to disclose. SR does not have any competing interests to disclose. BR has served as a consultant for Alexion Pharmaceuticals. WS does not have any competing interests to disclose. AS receives research support from Amylyx Pharmaceuticals, Alexion Pharmaceuticals, ALS Association, Mass General Hospital, NIH\/NINDS, and Cytokinetics Inc, and serves on an IDMC for Alexion. TM has served in an advisory capacity for Abbvie, Alexion, Amicus, Argenx, Audentes, Maze Therapeutics, Modis, Momenta, Ra Pharmaceuticals, Sanofi-Genzyme, Sarepta, Spark Therapeutics, UCB, and Ultragenyx. He serves on the speaker\u2019s bureau for Sanofi-Genzyme. Dr. Mozaffar serves on the medical advisory board for the Myositis Association, Neuromuscular Disease Foundation, Myasthenia Gravis Foundation of California and Myasthenia Gravis Foundation of America. Dr. Mozaffar receives research funding from the Myositis Association, the Muscular Dystrophy Association, the National Institutes for Health and from the following sponsors: Alexion, Amicus, Argenx, Audentes, Bristol-Myers-Squib, Cartesian Therapeutics, Grifols, Momenta, Ra Pharmaceuticals, Sanofi-Genzyme, Spark Therapeutics, UCB, and Valerion. He serves on the data safety monitoring board for Acceleron, Avexis, Sarepta, and the NIH. CW has served on advisory boards for Acceleron, Sarepta, Abata, and Orphazyme, and as a consultant for Sarepta. VK does not have any competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}